Clinton Group’s Kyntra Bio KYNB Stock Holding History

Clinton Group’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-481	Closed	-$297K	–	660
2017 Q1	$297K	Buy	+481	New	+$293K	0.02%	772

Other funds holding KYNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Clinton Group's KYNB Position: Q2 2017 in Review

Clinton Group sold out of Kyntra Bio (KYNB) in Q2 2017, closing a stake of 481 shares — an estimated $297K sold.

Clinton Group first reported a position in KYNB in Q1 2017 and held it in 1 quarter. The position peaked at $297K in Q1 2017. 151 funds tracked by Wall St. Rank hold KYNB as of Q2 2017.

Clinton Group reported no remaining Kyntra Bio position as of Q2 2017 after selling out during the quarter.
Clinton Group sold 481 Kyntra Bio shares in Q2 2017, an estimated $297K.
Clinton Group first reported a position in Kyntra Bio in Q1 2017 and held it in 1 quarter.
Clinton Group's Kyntra Bio position peaked at $297K in Q1 2017.
151 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2017.

Based on Clinton Group's 13F filing for Q2 2017, filed 14 Aug 2017.